Full-Time

R&D Change Management Expert

Deadline 8/31/26
Sanofi

Sanofi

10,001+ employees

Global pharma company; vaccines and R&D

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's

Category
Business & Strategy (1)
Required Skills
SharePoint
Communications
Risk Management
Marketing
Data Analysis

Get referred to Sanofi

See people who can refer or advise you

Requirements
  • A minimum of 5 years of experience in Pharmaceutical Research and Development, with understanding of Research and Development, clinical development, and regulatory environments.
  • At least 4 years of experience owning and leading change management, communications, and/or marketing in complex, matrixed organizations.
  • Leadership and meeting presence to build trust and credibility quickly.
  • Strategic thinking with the ability to connect change initiatives to broader business objectives.
  • Strong influencing skills without direct authority in a complex, matrixed environment, including the ability to engage stakeholders, manage expectations, and address concerns.
  • Comfort with ambiguity and the ability to navigate complex organizational dynamics.
  • Proficiency in change management principles, methodologies, and best practices.
  • Strong analytical skills to understand problems and business impacts and define solutions, including structured implementation plans.
  • Excellent verbal and written English communication skills, including the ability to create and edit communication content for intranets, Viva Engage, SharePoint, presentations, newsletters, videos, internal articles, and story text.
  • Strong problem-solving skills to evaluate proposed changes and their implications.
  • Capacity to identify risks, benefits, and potential obstacles.
  • Experience working cross-functionally and collaboratively with Research and Development, quality, and regulatory affairs teams.
  • Agility and resilience to handle evolving priorities and frequent adjustments.
  • A results-oriented mindset, autonomy, proactivity, and accountability.
  • Excellent active listening skills and the ability to understand change from the perspective of affected employees.
  • A bachelor's degree or equivalent in Life Sciences, Business, Communication, Marketing, or a related field.
  • Certification in change management is required, such as Prosci or Association of Change Management Professionals certification.
Responsibilities
  • Lead the development and implementation of change strategies and plans that maximize employee adoption and usage of required changes, using the standard change management playbook and approaches.
  • Build a trusted relationship with the Project or Program Manager and support the project or program as a credible change management adviser.
  • Identify and engage key stakeholders and secure their buy-in and support for complex initiatives involving multiple organizations and geographies.
  • Conduct change impact analyses and assess organizational readiness across process, technology, culture, and capability dimensions.
  • Design targeted change management plans based on analysis of impacted populations, concerns, and resistance patterns.
  • Develop and execute communication strategies across all channels for audiences ranging from frontline employees to leadership.
  • Define and track key performance indicators and success metrics for change adoption, utilization, and proficiency.
  • Use data-driven approaches to monitor adoption before, during, and after go-live.
  • Develop and execute mitigation plans to address resistance and accelerate adoption.
  • Ensure sustained adoption through structured hypercare and reinforcement strategies.
  • Report change effectiveness to senior leadership and provide actionable insights and recommendations.
  • Prepare, present, and communicate creative materials clearly to internal stakeholders.
  • Design, develop, deliver, and manage communications across channels and platforms and support adoption throughout the hypercare period.
  • Build, mobilize, and manage a Change Agent Network across impacted business areas, accountable for function-level adoption targets, user awareness, and post-go-live adoption tracking.
  • Assess and mitigate risks associated with change initiatives.
  • Ensure employees are adequately prepared for upcoming changes.
Desired Qualifications
  • Project management skills or experience are desired.
  • Familiarity with artificial intelligence and its application in change management is a plus.
  • French language skills are a plus.

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 17.8%; Dupixent topped €5.2 billion for the quarter.
  • July 30 upgraded 2026 guidance to around 10% sales growth, with higher EPS.
  • August 4 MenQuadfi infant approval widens vaccine reach; Nexviazyme's June phase 3 readout strengthens pipeline.

What critics are saying

  • Dupixent faces tougher H2 2026 comparisons, threatening growth after the €5.2 billion quarter.
  • Cenrifki carries liver injury risk; strict monitoring can slow adoption and invite liability.
  • Dupixent concentration and Regeneron's November 2024 lawsuit threaten Sanofi's core growth engine.

What makes Sanofi unique

  • Dupixent and partnered launch engine generate repeatable immunology cash flows across geographies.
  • Sanofi converted 2026 approvals for Sarclisa Escena, Wayrilz, and Cenrifki into launches.
  • Paulo Fontoura's September 1 R&D mandate centralizes translational science and regulatory execution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Business Wire
Aug 13th, 2026
Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Epicrispr Biotechnologies Closes $90 Million Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD

Morningstar
Aug 12th, 2026
InduPro raises $77M Series B, doses first patient in Phase 1 trial of bispecific ADC for lung cancer

InduPro has closed a $77 million Series B financing round and dosed its first patient in a Phase 1 study of IDP-001, its lead oncology programme. The biotechnology company is developing IDP-001, a bispecific antibody-drug conjugate targeting EGFR and a novel tumour-associated proximity antigen, for treating advanced squamous non-small cell lung cancer and other solid tumours. The Column Group led the financing round, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and Company. Proceeds will support Phase 1 clinical development and early proof-of-concept data generation for IDP-001, whilst advancing InduPro's broader preclinical pipeline. InduPro uses a proximity-guided platform to map protein spatial relationships on cell surfaces for discovering selective co-target pairs.

FinancialContent
Jul 24th, 2026
Scribe Therapeutics prices upsized $129M IPO at top of range

Scribe Therapeutics, a clinical-stage biotechnology company developing in vivo CRISPR technologies, has priced its upsized initial public offering at $15.00 per share, the high end of its range. The company is offering 8,580,000 shares, expecting to raise $128.7 million in gross proceeds before fees and expenses. Scribe has also granted underwriters a 30-day option to purchase up to 1,287,000 additional shares. The shares are expected to begin trading on the Nasdaq Global Market on 24 July 2026 under the ticker symbol "SCTX", with the offering closing on 27 July 2026. Additionally, Scribe has agreed to sell 500,000 shares at the same price to Sanofi in a concurrent private placement. Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities are serving as joint book-running managers.

Associated Press
Jul 10th, 2026
Sanofi's Sarclisa Escena approved in US as first anticancer drug delivered via on-body injector

The US Food and Drug Administration has approved Sanofi's subcutaneous Sarclisa Escena for treating multiple myeloma, making it the first anticancer treatment administered through an on-body injector. The therapy uses Enable Injections' CirCLIQ device, which delivers the drug automatically with a retractable 30g needle. The approval was supported by the IRAKLIA phase 3 study, which demonstrated that Sarclisa Escena delivered via the on-body injector provided similar efficacy and safety compared to intravenous infusion, with significantly shorter treatment time and fewer infusion-related reactions. The study showed a 71.1% objective response rate in patients with relapsed or refractory multiple myeloma. More than 70,000 patients worldwide have been treated with Sarclisa-based regimens. The on-body injector aims to reduce physical burden on healthcare providers whilst offering patients greater convenience during treatment.

Yahoo Finance
Jul 5th, 2026
Sanofi appoints Paulo Fontoura as R&D chief to accelerate pharma pipeline transformation

Sanofi has appointed Paulo Fontoura as Executive Vice President and Global Head of Research & Development Pharma, effective 1 September. Based in Paris, Fontoura will oversee the company's innovation engine, spanning research, translational medicine, clinical development, and regulatory affairs. He succeeds Dr Houman Ashrafian, who is leaving to pursue new opportunities. Fontoura brings over 25 years of experience across academic medicine, translational science, and pharmaceutical innovation. The appointment comes as Sanofi drives an R&D transformation whilst progressing its pipeline across multiple therapeutic areas. Separately, MacroGenics confirmed it will receive $24.5 million in regulatory milestone payments from Sanofi following FDA accelerated approval of TZIELD to delay decline in endogenous insulin production in children. Sanofi is a global biopharmaceutical company focusing on immunology, rare diseases, and oncology.